RxDoctor Payments Data

Lareina Albertson

Family · Bellingham, WANPI 1740703941

Payments from drug & device makers

$333in general payments, 2019–2025

Across 18 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$92
  • Gilead$91
  • Viiv Healthcare Company$54
  • Abbott$24
  • Napo Pharmaceuticals Inc$20
  • Jazz Pharmaceuticals Inc.$17
  • plus $35 from 3 others

What the payments were for

  • Speaking & faculty fees$206%
  • Food & beverage$31494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$333 in reported general payments places this provider in the 60th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$446
Medicare patients
23
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala176$712,189
GenvoyaElviteg/Cob/Emtri/Tenof Alafen56$217,169
TriumeqAbacavir/Dolutegravir/Lamivudi35$154,663
TivicayDolutegravir Sodium60$130,566
JulucaDolutegravir/Rilpivirine27$109,276
DescovyEmtricitabine/Tenofov Alafenam51$106,864
DovatoDolutegravir Sodium/Lamivudine37$102,403
JardianceEmpagliflozin68$77,846
OzempicSemaglutide72$66,445
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$60,096
PrezcobixDarunavir/Cobicistat23$56,800
TrulicityDulaglutide37$44,217
JanuviaSitagliptin Phosphate45$41,806
Abilify MaintenaAripiprazole13$25,732
XareltoRivaroxaban20$25,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$91$1,036,223283 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Juluca, Dovato$54$496,909159 claims
Johnson & JohnsonPrezcobix, Xarelto$92$81,91843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,706 family providers in Washington.

Other family in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →